Michel Vounatsos, Biogen CEO (via YouTube)

June 10, 2022 12:07 PM EDTUpdated 01:23 PM

Biogen yanks its Aduhelm application in Canada, days after celebrating the drug's 1-year anniversary in the US

Nicole DeFeudis

Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Regeneron makes $80M obesity deal with Hansoh

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Is there still hope for Summit's cancer drug buried in the data?

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

Updated: Omada Health rose 21% in its public market debut

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...